Fundraising FoxExSight Ventures — Full Portfolio
25 tracked investments · listed companies and verified rows first
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder and Chief Scientific Officer)inDavid Esposito(President and Chief Executive Officer)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)inJeffrey A Jamison(Executive Officer)in
BoardAaron Fletcher(Director)in
Co-investorsBios PartnersInvest MichiganNovartis Venture FundVisionary VenturesInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.
BiotechHealthtechMedical DevicesSan Diego, US
David Eveleth(Executive Officer, Director)inSchalon Newton(Executive Officer)in
BoardChristy Shaffer(Director)inRalph Bradshaw(Director)
Co-investorsBios PartnersHatteras Venture PartnersSolasta VenturesAccess BiotechnologyCorrelation VenturesFemHealth Ventures+1 more
HealthtechIrvine, US
JAMES TAYLOR(Executive Officer)IRVING ROBERT ARMSTRONG(Executive Officer)ROBERT SHIMIZU(Executive Officer)NARESH MANDAVA(Director)
BoardAKITERU FURUKAWA(Director)CLAUDE BENEDICT(Director)
Co-investorsInFocus Capital Partners, LLC
The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology.
BiotechHealthtechSan Diego, US
Arthur Suckow, Ph.D.(Founder)in
Co-investorsAccess BiotechnologyNuFund Venture GroupRA CapitalTachyon VenturesJanus Henderson Investors
Implant-free, minimally invasive glaucoma surgery (MIGS) creating microscopic channels in the eye to lower intraocular pressure.
A Japanese manufacturer and seller of billiard equipment, including cues, tips, and chalk, serving players and retailers worldwide through overseas distributors across 25+ countries.
Advanced ManufacturingConsumerHiroshima, JP
Masato Hiraoka(Chairman)Kazumi Kuwahara(President)
Co-investorsD CapitalNuFund Venture GroupRockies Venture ClubGICNP-Hard Ventures
Horizon Surgical Systems develops surgical robotics for ophthalmic procedures, with a focus on improving cataract surgery.
AI & Machine LearningHealthtechMedical DevicesRobotics
Jacob Rosen(Founder)in
Springer is an academic and scientific publisher with a portfolio of over 2,700 journals and more than 220,000 books, serving researchers, authors, readers, and institutions worldwide.
Media & Entertainment
Co-investorsChanzo Capital
LensGen is an ophthalmic medical device company that has developed Juvene, a curvature-changing fluid-optic intraocular lens designed to treat cataracts and presbyopia.
BiotechHardwareHealthtechMedical DevicesIrvine, US
Ramgopal Rao(Founder & Chief Executive Officer)
BoardAkiteru Furukawa(Director)Michael Colaco(Director)Shivbir Grewal(Director)
Novai applies advanced molecular and computational approaches to eye disease, supporting clinicians and researchers in translating scientific findings into patient treatment options.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesReading, GB
Prof. Francesca Cordeiro(Founder, Director & Chief Executive Officer)Prof. M. Francesca Cordeiro(Founder & CEO)MARIA FRANCESCA CORDEIRO(Director)
BoardNATALIE PANKOVA(Director)inKARL DAVID KEEGAN(Director)STEPHEN ROY PAGE(Director)
Co-investorsAnglia Capital GroupAscensionConduit ConnectThe FSE GroupInBC Investment Corp.Zinc
Novartis is a pharmaceutical company that develops and markets prescription medicines for patients across therapeutic areas including multiple sclerosis, breast cancer, and inflammatory conditions.
BiotechHealthtechBasel, CH
Co-investorsClal Biotechnology IndustriesLongitude CapitalTachyon VenturesThe Column Group
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration.
BiotechMedical DevicesBerkeley, US
Wesley Jackson(President, Chief Scientific Officer & Member of the Board)inGregory D. Kunst(Chief Executive Officer)Carole H Bellis(Executive Officer)Kevin E Healy(Director)Jackson M Wesley(Executive Officer, Director)
BoardDrew Lanza(Director)in
Co-investorsAngel Physicians FundBerkeley CatalystFirst Spark Ventures, LlcPandect BioventuresTaihill Venture
Vana is an open data infrastructure platform that enables individuals to control and manage the data they generate, with the ability to choose how it is used by AI systems.
AI & Machine LearningCrypto & Web3Data & Infrastructure
Art Abal(Founder)Anna Kazlauskas(Founder)
Co-investorsAbstract VenturesAlphaLab CapitalBoxGroupCaladanEarl Grey CapitalFlori Ventures+15 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AjoELIOSEnvision DiagnosticsLwwRe-vanaRe-Vana TherapeuticsRetroSense TherapeuticsRevOpsis Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.